Last reviewed · How we verify
Licensed TIV-HD1
TIV-HD1 is a high-dose trivalent inactivated influenza vaccine designed to provide enhanced immune protection against three influenza virus strains.
TIV-HD1 is a high-dose trivalent inactivated influenza vaccine designed to provide enhanced immune protection against three influenza virus strains. Used for Seasonal influenza prevention in adults, particularly elderly populations.
At a glance
| Generic name | Licensed TIV-HD1 |
|---|---|
| Also known as | High-dose trivalent influenza vaccine |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Drug class | Inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
As a high-dose formulation of the seasonal trivalent inactivated influenza vaccine (TIV), TIV-HD1 contains increased antigen content compared to standard-dose vaccines, intended to elicit a stronger and more robust immune response. This enhanced immunogenicity is particularly aimed at improving protection in populations with weaker immune responses, such as elderly individuals. The vaccine works by stimulating both humoral and cellular immunity against the three included influenza virus strains (typically two A subtypes and one B lineage).
Approved indications
- Seasonal influenza prevention in adults, particularly elderly populations
Common side effects
- Injection site pain or erythema
- Myalgia
- Headache
- Fatigue
Key clinical trials
- Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US (PHASE3)
- A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |